DeepMed Research

Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Atorvastatin
Drug: Ezetimibe
Drug: Alirocumab
Drug: Placebo

First Posted Date: 2012-10-18

Last Posted Date: 2020-06-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 314

Registration Number: NCT01709513

Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: nesvacumab (REGN910/ SAR307746)
Drug: aflibercept (ziv-aflibercept)

First Posted Date: 2012-09-20

Last Posted Date: 2015-03-17

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01688960

Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo (for Dupilumab)
Drug: Dupilumab
Other: Topical Corticosteroid (TCS)

First Posted Date: 2012-07-12

Last Posted Date: 2017-10-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT01639040

Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

Phase 1

Terminated

Conditions: Pruritus
Atopic Dermatitis

Interventions: Drug: REGN846

First Posted Date: 2012-05-25

Last Posted Date: 2013-10-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT01605708

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Phase 2

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Alirocumab
Drug: Placebo

First Posted Date: 2012-05-24

Last Posted Date: 2020-06-17

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT01604824

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Phase 2

Completed

Conditions: Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia

Interventions: Drug: Placebo Matched to Alirocumab
Drug: Alirocumab

First Posted Date: 2012-04-12

Last Posted Date: 2020-08-05

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 58

Registration Number: NCT01576484

Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Dupilumab

First Posted Date: 2012-03-08

Last Posted Date: 2018-08-10

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 109

Registration Number: NCT01548404

Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN1154 or placebo

First Posted Date: 2012-02-28

Last Posted Date: 2014-01-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT01540539

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Phase 3

Completed

Conditions: Branch Retinal Vein Occlusion

Interventions: Procedure: Macular Laser Photocoagulation
Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

First Posted Date: 2012-01-30

Last Posted Date: 2014-11-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 183

Registration Number: NCT01521559

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN1033(SAR391786)
Drug: Placebo

First Posted Date: 2012-01-10

Last Posted Date: 2012-11-14

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT01507402

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy